Locations:

Tag: stanley hazen

April 19, 2024/Basic & Translational Science

Cleveland Clinic, Tufts University Research Ties Gut Microbial TMAO Pathway to Chronic Kidney Disease

Large-scale joint study links elevated TMAO blood levels and chronic kidney disease risk over time

November 15, 2021/Cancer

Study Links the Gut Microbiome and Aggressive Prostate Cancer

Findings from the prospective analysis and implications for diagnosing, preventing lethal prostate cancer

December 12, 2018/Basic & Translational Science

Teasing Out the Role of Red Meat and TMAO in Cardiovascular Risk

Two new studies add insights and home in on therapeutic targets

August 7, 2018/Basic & Translational Science

Nonlethal Targeting of Gut Microbes Inhibits Thrombosis with Minimal Bleeding Risk

Mouse study shows most potent therapeutic ‘drugging’ of microbiome to date

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

November 16, 2017/Heart, Vascular and Thoracic/News & Insights

Cleveland Clinic’s Stanley Hazen, MD, PhD, Named a 2017 AHA Distinguished Scientist

Honored for multiple discoveries in atherosclerosis, including role of the gut microbiome

July 21, 2017/Diabetes & Endocrinology

TMAO-Producing Enzyme Shown to Regulate Obesity in Humans

Extension of the gut microbial pathway has therapeutic implications for obesity, diabetes

May 8, 2017/Heart, Vascular and Thoracic/Research

Gut Microbe-Dependent TMAO from Dietary Choline Found to Be Prothrombotic in Humans

And platelet responsiveness appears to be attenuated by aspirin

Acute coronary syndrome (ACS)/chest pain

January 31, 2017/Heart, Vascular and Thoracic/Research

TMAO Proves a Potent Predictor of Events in Acute Coronary Syndrome

Study finds strong prognostic value even in patients with negative baseline troponin T

September 23, 2015/Rheumatology & Immunology/Rheumatic Diseases

In Psoriatic Diseases, HDL-Associated Antioxidant Enzymes Show Promise as a Cardiac Risk Tool

First study of paraoxonase-1 activity levels in psoriatic diseases

BackPage 1 of 1Next